Bivalirudin
Published date: 2026-05-22 13:54:14
|
Name | Bivalirudin trifluoroacetate salt | CAS# | 128270-60-0 |
|---|---|---|---|---|
| Price | $99.89/10mg $1692.0/1g | Purity | 99.21% | |
| Stocking Period |
3 Day | Stock | In Stock | |
| Product Webpage: | http://www.zhaokebio.com | |||
| Detail
Product Information
Bivalirudin is a synthetic 20-amino acid peptide and a direct thrombin inhibitor used as an anticoagulant in percutaneous coronary intervention (PCI) and for the treatment of heparin-induced thrombocytopenia (HIT). It consists of a hirudin-like N-terminal domain that binds to thrombin's active site and a C-terminal domain that interacts with the fibrinogen recognition exosite, providing rapid and predictable anticoagulation with a short half-life. Product Highlights: 1. Direct Thrombin Inhibition-Directly inhibits both free and clot-bound thrombin without requiring antithrombin III cofactor, providing rapid onset anticoagulation. Predictable anticoagulant effect with minimal patient variability; no routine monitoring required (unlike heparin). 2. Short Half-Life Advantage-Plasma half-life of only ~25 minutes with enzymatic degradation and renal clearance; anticoagulant effect dissipates within 1-2 hours of stopping infusion. Rapidly reversible anticoagulation reduces bleeding risk; ideal for procedures where fast hemostasis is needed. 3. HIT Treatment Standard HIT-FDA-approved for heparin-induced thrombocytopenia (HIT) and HIT with thrombosis syndrome (HITTS) where heparin is contraindicated. Fills critical gap in anticoagulation for HIT patients; avoids cross-reactivity with heparin-PF4 antibodies. 4. PCI Procedural Efficacy PCI-Demonstrated non-inferiority to heparin in percutaneous coronary intervention (PCI) with reduced bleeding complications in REPLACE-2 trial. Growing adoption in interventional cardiology for PCI anticoagulation, particularly in high-risk bleeding patients. 5. Linear Peptide Simplicity-Linear 20-amino acid peptide with straightforward solid-phase synthesis and well-established analytical methods. Reliable synthesis and quality control at scale; consistent batch-to-batch reproducibility for commercial supply. 6. GMP Commercial Supply GMP-Multi-kilogram GMP manufacturing capacity with full regulatory documentation (DMF, stability data, method validation). Proven supply chain supporting global generic developers with batch records for FDA, EMA, and NMPA submissions. 7. Full-Service API Partner -Integrated supply of Bivalirudin API, impurity standards, reference materials, and thrombin inhibition assay support. End-to-end procurement reduces vendor management complexity and accelerates formulation partner time-to-market. |